Jove
Visualize
Contact Us

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding Variants in EGFR Exon 20 Insertions: Guiding Therapy Beyond a One-Size-Fits-All Approach.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?

Cancer treatment reviews·2026
Same author

PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC.

Journal of biomedical science·2025
Same author

Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same journal

Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Genomic Landscape and Clinical Impact of MTAP Loss in Driver-Positive NSCLC: Insights from a Large-Scale Real-World Chinese Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Germline Mutations as Risk Factors for Lung Cancer: A Systematic Review and Meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A Response to the Letter to the Editor: Population-informed Assessment of Clonality in Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

Is Less Actually More? Precision Is the Key!

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same journal

A Response to the Letter to the Editor: Supporting a Neuroprotective Effect of Lorlatinib Across ALK and ROS1 Targets.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 8, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Beyond PACIFIC: Rethinking Consolidation in Molecularly Defined Stage III NSCLC

Hsin-Tuan Huang1, Derek De-Rui Huang2

  • 1Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|June 6, 2026
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: Jun 8, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023